 |
23 Diseases |  |
10 Trials |
|
10 Trials |  |
138 News |  |
| «123» |
- | Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial initiation date: Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - Jul 1, 2019
P1, N=144, Not yet recruiting, Sponsor: University of Virginia
Initiation date: Apr 2019 --> Aug 2019
- | Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
Phase classification: Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - May 2, 2019
P1, N=144, Not yet recruiting, Sponsor: University of Virginia
Initiation date: Apr 2019 --> Aug 2019 Phase classification: P=N/A --> P1
- | estradiol valerate / Generic mfg.
Trial completion date, Trial primary completion date: Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient (clinicaltrials.gov) - Apr 16, 2019
P=N/A, N=450, Recruiting, Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
Phase classification: P=N/A --> P1 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Oct 2019
- | Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance, Ovidrel (choriogonadotropin alfa) / EMD Serono
New P1 trial, New trial: Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov) - Apr 5, 2019
P=N/A, N=144, Not yet recruiting, Sponsor: University of Virginia
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Trial completion: Triggering of Follicular Maturation (clinicaltrials.gov) - Mar 20, 2019
P3, N=160, Completed, Sponsor: Assiut University
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Oct 2019 Recruiting --> Completed
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
New trial: AMJH: Follicle Size and Oocyte Development (clinicaltrials.gov) - Sep 7, 2018
P=N/A, N=200, Recruiting, Sponsor: Sheba Medical Center
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, diclofenac sodium topical patch (HP-5000) / Hisamitsu
New trial: Natural Cycles With Spontaneous Versus Induced Ovulation in FET (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=2866, Completed, Sponsor: Istituto Clinico Humanitas
- | hydrocortisone / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction (clinicaltrials.gov) - Jul 19, 2018
P1, N=0, Withdrawn, Sponsor: University of Virginia
Recruiting --> Completed N=20 --> 0 | Trial completion date: Dec 2019 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Vagifem (estradiol) / Novo Nordisk, Estrofem (estradiol oral) / Novo Nordisk
New trial: Endometrial Preparation in Frozen Embryo Transfer Cycles (clinicaltrials.gov) - Jul 16, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Meir Medical Center
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
New P4 trial, BRCA Biomarker: Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers (clinicaltrials.gov) - Jul 15, 2018
P4, N=35, Recruiting, Sponsor: University Hospital, Ghent
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion date, Trial primary completion date: IVF Treatment in Women With Immature Oocytes in Previous Cycle (clinicaltrials.gov) - Jul 6, 2018
P=N/A, N=100, Recruiting, Sponsor: Sheba Medical Center
N=20 --> 0 | Trial completion date: Dec 2019 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018 Trial completion date: Jun 2017 --> Jun 2020 | Trial primary completion date: Jun 2017 --> Jun 2020
- ||| estradiol valerate / Generic mfg.
Enrollment open: Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient (clinicaltrials.gov) - May 28, 2018
P=N/A, N=450, Recruiting, Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
Trial completion date: Jun 2017 --> Jun 2020 | Trial primary completion date: Jun 2017 --> Jun 2020 Not yet recruiting --> Recruiting
- ||||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion: FASHION: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - Mar 27, 2018
P3, N=176, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| progesterone / Generic mfg., letrozole / Generic mfg.
New P2/3 trial: Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole (clinicaltrials.gov) - Feb 22, 2018
P2/3, N=52, Completed, Sponsor: Eastern Virginia Medical School
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial primary completion date: Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) - Jan 23, 2018
P=N/A, N=80, Recruiting, Sponsor: University of Virginia
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
- | hydrocortisone / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction (clinicaltrials.gov) - Jan 23, 2018
P1, N=20, Not yet recruiting, Sponsor: University of Virginia
Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P=N/A --> P1 | Initiation date: Apr 2017 --> Jun 2018 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Enrollment open: Triggering of Follicular Maturation (clinicaltrials.gov) - Nov 14, 2017
P3, N=148, Recruiting, Sponsor: Assiut University
Phase classification: P=N/A --> P1 | Initiation date: Apr 2017 --> Jun 2018 | Trial primary completion date: Jun 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- ||| estradiol valerate / Generic mfg.
New trial: Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient (clinicaltrials.gov) - Oct 3, 2017
P=N/A, N=450, Not yet recruiting, Sponsor: Reproductive & Genetic Hospital of CITIC-Xiangya
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon
Trial completion, Preclinical, Trial primary completion date: Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. (clinicaltrials.gov) - Jun 12, 2017
P3, N=234, Completed, Sponsor: Instituto de Investigacion Sanitaria La Fe
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Jun 2017
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon
Preclinical, Trial primary completion date: Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. (clinicaltrials.gov) - Jun 8, 2017
P3, N=232, Recruiting, Sponsor: Instituto de Investigacion Sanitaria La Fe
Recruiting --> Completed | Trial primary completion date: Sep 2017 --> Jun 2017 Trial primary completion date: Jan 2017 --> Sep 2017
- ||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment closed, Enrollment change: FASHION: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - Apr 11, 2017
P3, N=180, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jan 2017 --> Sep 2017 Recruiting --> Active, not recruiting | N=258 --> 180
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial primary completion date: Ovarian Contribution to Androgen Production in Adolescent Girls (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=80, Recruiting, Sponsor: University of Virginia
Recruiting --> Active, not recruiting | N=258 --> 180 Trial primary completion date: Dec 2015 --> Dec 2017
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open: Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study (clinicaltrials.gov) - Dec 13, 2016
P4, N=62, Recruiting, Sponsor: Sheba Medical Center
Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial primary completion date: FASHION: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - Oct 21, 2016
P3, N=258, Recruiting, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2016 --> Jul 2017
- || Ovidrel (choriogonadotropin alfa) / EMD Serono, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
New P3 trial: Triggering of Follicular Maturation (clinicaltrials.gov) - Sep 27, 2016
P3, N=148, Not yet recruiting, Sponsor: Assiut University
- Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon
Preclinical, Trial primary completion date: Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. (clinicaltrials.gov) - Sep 8, 2016
P3, N=232, Recruiting, Sponsor: Instituto de Investigacion Sanitaria La Fe
Trial primary completion date: Nov 2016 --> Jul 2017 Trial primary completion date: Sep 2015 --> Jan 2017
- || Ovidrel (choriogonadotropin alfa) / EMD Serono
New P3 trial: Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles (clinicaltrials.gov) - Aug 11, 2016
P3, N=1000, Not yet recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
- | Ovidrel (choriogonadotropin alfa) / EMD Serono
New P4 trial: Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study (clinicaltrials.gov) - Jul 7, 2016
P4, N=62, Not yet recruiting, Sponsor: Sheba Medical Center
- Ovidrel (choriogonadotropin alfa) / EMD Serono
New trial: Dual Triggering in Patients With a High Immature Oocyte Rate (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=81, Completed, Sponsor: IVI Madrid
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial primary completion date: IVF Treatment in Women With Immature Oocytes in Previous Cycle (clinicaltrials.gov) - Jun 20, 2016
P=N/A, N=100, Recruiting, Sponsor: Sheba Medical Center
Trial primary completion date: Sep 2015 --> Jan 2017 Trial primary completion date: Feb 2016 --> Jun 2017
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment change, Trial withdrawal: The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes (clinicaltrials.gov) - May 26, 2016
P=N/A, N=0, Withdrawn, Sponsor: Antalya IVF
Trial primary completion date: Feb 2016 --> Jun 2017 N=800 --> 0 | Recruiting --> Withdrawn
- |||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open: FASHION: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - May 5, 2016
P3, N=258, Recruiting, Sponsor: Ferring Pharmaceuticals
N=800 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment closed: Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders (clinicaltrials.gov) - Jan 20, 2016
P4, N=150, Active, not recruiting, Sponsor: Eugonia
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open, Enrollment change, Trial initiation date: Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders (clinicaltrials.gov) - Dec 23, 2015
P4, N=150, Recruiting, Sponsor: Eugonia
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=200 --> 150 | Initiation date: Jun 2004 --> Jun 2013
- ||| Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
New trial: GnRH: Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Chong Qing Reproducive and Genetic Institute
- |||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion: Endometrial Advancement After Rec or u-HCG Triggering (clinicaltrials.gov) - Dec 5, 2015
P4, N=130, Completed, Sponsor: Universitair Ziekenhuis Brussel
Active, not recruiting --> Recruiting | N=200 --> 150 | Initiation date: Jun 2004 --> Jun 2013 Active, not recruiting --> Completed
- ||||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion, Trial primary completion date: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Sep 9, 2015
P3, N=941, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2015
- ||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment change, Trial primary completion date: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Jun 29, 2015
P3, N=941, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Mar 2015 N=1365 --> 941 | Trial primary completion date: May 2015 --> Aug 2015
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion, Enrollment change, Trial primary completion date: Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures (clinicaltrials.gov) - Jun 6, 2015
P4, N=3, Completed, Sponsor: Rambam Health Care Campus
N=1365 --> 941 | Trial primary completion date: May 2015 --> Aug 2015 Recruiting --> Completed | N=100 --> 3 | Trial primary completion date: Jan 2016 --> Jan 2015
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment change: Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - May 28, 2015
P=N/A, N=36, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed | N=100 --> 3 | Trial primary completion date: Jan 2016 --> Jan 2015 N=50 --> 36
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open, Phase classification, Enrollment change, Trial primary completion date: The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes (clinicaltrials.gov) - May 27, 2015
P=N/A, N=800, Recruiting, Sponsor: Antalya IVF
N=50 --> 36 Terminated --> Recruiting | Phase classification: P4 --> PN/A | N=400 --> 800 | Trial primary completion date: Mar 2015 --> Jun 2016
- |||||||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
New P3 trial: FASHION: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - May 20, 2015
P3, N=258, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open: IVF Treatment in Women With Immature Oocytes in Previous Cycle (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=100, Recruiting, Sponsor: Sheba Medical Center
Terminated --> Recruiting | Phase classification: P4 --> PN/A | N=400 --> 800 | Trial primary completion date: Mar 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- Ovidrel (choriogonadotropin alfa) / EMD Serono, Vagifem (estradiol) / Novo Nordisk, Estrofem (estradiol oral) / Novo Nordisk
Trial completion, Enrollment change: The Luteal Phase After GnRHa Trigger - a Proof of Concept Study (clinicaltrials.gov) - Mar 10, 2015
P4, N=93, Completed, Sponsor: Regionshospitalet Viborg, Skive
Not yet recruiting --> Recruiting Recruiting --> Completed | N=180 --> 93
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Clinical: IVF Treatment in Women With Immature Oocytes in Previous Cycle (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=100, Not yet recruiting, Sponsor: Sheba Medical Center
- || Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion, Enrollment change: Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Dec 12, 2014
P3, N=24, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed | N=180 --> 93 Recruiting --> Completed | N=75 --> 24
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial completion: Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=50, Completed, Sponsor: University of California, San Diego
Recruiting --> Completed | N=75 --> 24 Recruiting --> Completed
- Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment open, Trial initiation date: Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures (clinicaltrials.gov) - Nov 5, 2014
P4, N=100, Recruiting, Sponsor: Rambam Health Care Campus
Recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Oct 2014
- ||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Enrollment closed, Enrollment change: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Aug 15, 2014
P3, N=1310, Active, not recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Oct 2014 Recruiting --> Active, not recruiting | N=946 --> 1310
- letrozole / Generic mfg.
Trial primary completion date: Use of High Cost Monitoring During Letrozole Ovulation Induction (clinicaltrials.gov) - Jun 12, 2014
P4, N=21, Completed, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | N=946 --> 1310 Trial primary completion date: Jul 2012 --> Mar 2013